Johnson & Johnson announced on November 16 that it agreed to acquire Ollin Biosciences for US$2.2 billion upfront, with up to approximately US$1.125 billion more tied to regulatory and commercial milestones. The proposed deal would add OLN324, an experimental treatment for retinal diseases, to Johnson & Johnson’s drug pipeline. Axios reported on the deal and its financing at 15:06 UTC on November 16.
Johnson & Johnson expects the acquisition to close by the end of 2026, subject to regulatory approvals and other closing conditions. Once the deal closes, funds managed by Blackstone Life Sciences would provide US$750 million over several years to support late-stage trials under a separate agreement.
What would Johnson & Johnson get from the deal?
Ollin is developing OLN324 for conditions including wet age-related macular degeneration and diabetic macular edema, which affect the retina at the back of the eye. Johnson & Johnson describes OLN324 as a bispecific antibody, an engineered protein designed to bind to two targets. In this case the targets are two proteins involved in retinal disease.
Phase 3 is a late stage of clinical testing used to assess how well a treatment works and what side effects it causes. The program gives Johnson & Johnson a candidate to develop. Its future contribution to sales depends on trial results, decisions by drug regulators and uptake if it reaches the market.
How does Blackstone’s funding change the economics?
The Blackstone agreement concerns development spending. If the acquisition closes, Blackstone would take on the cost of the Phase 3 program under the disclosed arrangement. In return it could receive payments when regulatory and sales milestones are reached, plus royalties, which are payments tied to sales.
That arrangement shares development costs and some of the potential commercial proceeds. Investors following the deal can track the acquisition closing, the trial results and any later approval as separate milestones. Johnson & Johnson says it will explain the accounting treatment by the time the acquisition closes.
Go to the source
For general education. Consider your circumstances and local rules before making investment decisions. Figures describe the dates stated in this article and are not live market quotes.
Build your investing knowledge